Microscopic view of stained plant tissue cells showing pink xylem vessels and teal cellular structures in a cross-section sample.
Solutions

One evidence partner, built for every decision in your clinical program

Trials begin where the regulatory pathway demands — often without the longitudinal evidence that would inform protocol design, population selection, and feasibility upstream, or the post-approval evidence and access strategy that would be sharpened by understanding how the same patients move through care.

Pedestal Health is built to change both: an integrated evidence partner with the cohorts, technology, and clinical relationships to support your evidence strategy from clinical development to care delivery.

Researcher in blue glove holds a six-well plate showing purple-stained cell cultures with varying colony growth for laboratory analysis.

One model. Evidence across the program.

Pedestal Health's longitudinal cohorts support evidence generation that compounds over time — insights from our longitudinal cohort data shape the trials and prospective studies we run, and what those studies produce flows back into the cohorts as therapies move into care.

Each phase strengthens the next, rather than starting from scratch. The model supports three categories of decisions, each grounded in the same underlying infrastructure.

R&D Decisions

  • Clinical development

  • Translational and Study teams

  • Program teams

  • Disease characterization, natural history, biomarker work, and feasibility informed by longitudinal cohort data.

  • Protocol design and population selection grounded in real clinical contexts.

  • Prospective studies and clinical trials run within Pedestal's cohort and site infrastructure.

  • External control arms.

  • Sub-phenotyping and risk stratification.

Approval & Commercialization Decisions

  • Regulatory

  • HEOR / Market Access

  • Payers

  • Medical Affairs

  • Post-authorization safety studies.

  • Supplementation of regulatory submissions with longitudinal evidence.

  • External control arm contributions to FDA and EMA filings.

  • Comparative effectiveness.

  • Market access evidence.

  • Publication strategy and support.

Care Decisions

  • Clinicians

  • Health systems

  • Care delivery teams

  • PI-led research

  • Treatment pattern characterization in routine practice.

  • Long-term effectiveness and safety.

  • Clinical decision support evidence.

  • Therapeutic inertia and treat-to-target gap analyses.

  • Partnership infrastructure for clinician-led research and publications.

Hepatology

Dermatology

Gastroenterology

Future Disease Areas

One system, built for every decision a program faces

Our work has shown us what the field actually needs: not just another retrospective data source or another standalone clinical trial, but a hybrid system that keeps generating evidence on the same patients as the questions evolve. Our approach guides the decisions that matter most to clinical programs in active development as they arise:

Deep baseline characterization

At enrollment, we capture structured and unstructured EHR data and patients consent to prospective data collection. The starting point is richer than claims or registry data alone, and the same patient stays in the system from there.

Longitudinal follow-up

The same patients, followed over years. Continuously updated structured and unstructured EHR data alongside the prospectively collected measures from enrollment. The substrate for natural history, disease characterization, treatment patterns, and comparative effectiveness.

Partner-specific extensions

Programs that need additional PROs, biomarkers, imaging, or other measures can activate them through dedicated protocols layered on the same patient population.

Clinical trial infrastructure

A network of activated sites and a continuously enrolled patient population already in the system, ready to support embedded prospective studies, external control arms, and trial work that draws on what's already running.

Post-approval evidence

Patients enrolled before approval and followed past launch on the same continuous infrastructure, with partner-specific protocols providing the rigorous structure required for post-authorization safety, real-world effectiveness, and long-term outcomes work.

Macro photograph of translucent oil bubbles on a vibrant orange and red gradient background, evoking scientific and biological imagery.

Contact us

By submitting this form, you consent to your information used by Pedestal Health for the purpose of contacting you to better understand your potential interest in Pedestal Health and/or its services. For more information, see our privacy policy.